OptiBiotix Health PLC Distribution agreement for CholBiome (5596M)
09 January 2019 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 5596M
OptiBiotix Health PLC
09 January 2019
OptiBiotix Health plc
("OptiBiotix")
Distribution agreement for cholesterol reducing CholBiome(R)
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces it has entered into a three
year distribution agreement with SilvEXPO Ltd. ("SilvExpo") to
distribute and commercialise OptiBiotix's own label CholBiome(R)
products containing its cholesterol and blood pressure reducing
LP(LDL) (R) strain in Russia and Kazakhstan.
SilvExpo is an emerging company in the pharmaceutical and
nutraceutical industry, which has been working on transforming
fresh ideas and technologies into next generation products since
its inception. SilvExpo was setup following ten years of scientific
work, focusing on the export of high quality next generation food
supplements to partners in a wide range of countries including
Singapore, Armenia, Vietnam, Korea, Malaysia, Bulgaria, France,
Russia and Kazakhstan. Based on the company's experience in Russia
and Kazakhstan, LP(LDL) (R) containing product CholBiome(X3) (R)
was chosen as the first product from ProBiotix Health to be offered
and introduced into the chain of pharmacies in these countries.
The agreement grants SilvExpo non-exclusive distribution rights
for CholBiome(R) and extends the sales channel of the CholBiome(R)
range of products into the largest Eastern European markets for
probiotics. The Russian probiotics market alone is estimated at
EUR340 million with a 10% annual growth (Euromonitor). This is
another step in OptiBiotix's strategy to expand sales of
CholBiome(R) own label products into a growing number of
international markets. Russia and Kazakhstan have some of the
highest mortality rates in Eastern Europe caused by cardiovascular
disease accounting for up to 56% of all deaths (WHO). CholBiome(R)
products containing LP(LDL) (R) have a unique ability to reduce
both cholesterol and blood pressure providing a clinically proven
natural product to help reduce these cardiovascular risk factors in
countries with a high prevalence of these conditions.
Per Rehné, Commercial Director of OptiBiotix, commented: "We are
pleased to announce this agreement which extends the sales channel
of our CholBiome(R) products into Russia and Kazakhstan where
cardiovascular disease are the leading cause of morbidity and
mortality. We chose SilvExpo for its knowledge and speed to market
and they have shown the ability to grow product sales in
challenging markets. This agreement is a strategic step to build
the distribution sales channel for CholBiome(R) products in Eastern
Europe and we anticipate that the agreement could produce revenues
quickly."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRLLFVALRITIIA
(END) Dow Jones Newswires
January 09, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024